The 1-min sit-to-stand test as a screening tool to assess exercise-induced oxygen desaturation in normoxemic people with interstitial lung disease.

Autor: Visser S; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, Australia; University of Sydney, Faculty of Medicine and Health, Sydney, Australia. Electronic address: simone.visser@health.nsw.gov.au., Lawler C; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, Australia; University of Sydney, Faculty of Medicine and Health, Sydney, Australia; Centre of Research Excellence in Pulmonary Fibrosis, Australia., Fermoyle CC; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, Australia; University of Sydney, Faculty of Medicine and Health, Sydney, Australia; Centre of Research Excellence in Pulmonary Fibrosis, Australia., Spencer LM; Department of Physiotherapy, Royal Prince Alfred Hospital, Sydney, Australia., McAnulty AJ; Department of Physiotherapy, Royal Prince Alfred Hospital, Sydney, Australia., Alison JA; University of Sydney, Faculty of Medicine and Health, Sydney, Australia; Allied Health, Sydney Local Health District, Sydney, Australia., Webster S; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, Australia., Troy L; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, Australia; University of Sydney, Faculty of Medicine and Health, Sydney, Australia; Centre of Research Excellence in Pulmonary Fibrosis, Australia., Jo H; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, Australia; University of Sydney, Faculty of Medicine and Health, Sydney, Australia., Hayen A; School of Public Health, University of Technology Sydney, Sydney, Australia., Corte TJ; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, Australia; University of Sydney, Faculty of Medicine and Health, Sydney, Australia; Centre of Research Excellence in Pulmonary Fibrosis, Australia.
Jazyk: angličtina
Zdroj: Respiratory medicine [Respir Med] 2024 Oct; Vol. 232, pp. 107748. Date of Electronic Publication: 2024 Jul 27.
DOI: 10.1016/j.rmed.2024.107748
Abstrakt: Background: In patients with interstitial lung disease (ILD), exercise-induced desaturation during the 6-min walk test (6MWT), specifically nadir oxygen saturation (nSpO2) of ≤88 % is a negative prognostic marker. As the 6MWT is often impractical for ILD patients, the aim of this study is to compare the 1-min sit-to-stand test (1minSTS) with the 6MWT to detect exercise-induced desaturation.
Methods: Participants were recruited from a tertiary referral clinic with both tests performed on the same day. Utilising Bland-Altman analysis, the relationship between nSpO2 on 1minSTS and 6MWT was determined. An area under the receiver operating characteristic curve (AUC) determined the ability of nSpO2 on 1minSTS test to predict SpO2 ≤88 % on 6MWT.
Results: Fifty participants completed the study (idiopathic pulmonary fibrosis n = 24, 48 %; connective tissue disease associated ILD n = 20, 40 %; other ILD n = 6, 12 %). Mean (SD) FVC%pred was 73 ± 16 %, mean DLCO%pred 57 ± 16 % and resting SpO2 99 ± 1 %. The 1minSTS resulted in less exercise-induced oxygen desaturation, with a median IQR nSpO2 of 95 % (89-98) and 93 % (85-96) respectively (p < 0.001). Moderate agreement was determined between the nSpO2 on both tests, with a mean difference of 3.2 % [-14 to +3.0 %]. The 1minSTS test accurately identified participants with nSpO2 ≤88 % on 6MWT (AUC 0.96). Oxygen desaturation ≤94 % during the 1minSTS test provided 100 % sensitivity and 87 % specificity for oxygen desaturation ≤88 % at 6MWT.
Conclusion: This study demonstrates that exercise-induced oxygen desaturation during the 1minSTS test correlates with oxygen desaturation on 6MWT. The 1minSTS may be a practical screening tool for ILD patients who would benefit from further exercise testing.
Competing Interests: Declaration of competing interest There are no conflicts of interest to declare that directly relate to this manuscript. Unrelated to the current work LT reports speaker's fees from Boehringer Ingelheim and Erbe Elektromedezin GbH, and prior in-kind research support from Air Liquide Healthcare. TJC reports grants or contracts from Boehringer Ingleheim, Pharmaxis, Bristol Myers Squibb, 4D, Roche, Pliant, Bridge Biotherapeutics and Avalyn Therapeutics; consulting fees with Boehringer Ingleheim, Pharmaxis, Bristol Myers Squibb, 4D, Roche, Pliant Bridge Biotherapeutics, Avalyn Therapeutics, DevPro, Endeavour, BioMedicine and Cincera; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bristol Myers Squibb, Roche and Boehringer Ingleheim; support for attending meetings and/or travel with Bristol Myers Squibb and Boehringer Ingelheim; participation on a data safety monitoring board or advisory Board with Boehringer Ingleheim, Bristol Myers Squibb, Roche, Pliant, Bridge Biotherapeutics, Avalyn Therapeutics, DevPro and Endeavour BioMedicine. SW has received an educational grant from Boehringer Ingleheim.
(Copyright © 2024. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: